Evidence map›Paper›PMID 36589621›Full record

ArticleFrontiers in surgery2022

Chemoradiotherapy with 3-weekly CDDP 80 mg/m

Kohei Otaki, Takeshi Takahashi, Ryoko Tanaka, Kohei Saijo, Jo Omata, Yusuke Yokoyama, Ryusuke Shodo, Yushi Ueki, Keisuke Yamazaki, Hisayuki Ota and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Anemia, as an adverse event during chemoradiotherapy for head and neck cancer, contributes to a reduction in swallowing muscle mass and leads to dysphagia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Kohei OtakiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Takeshi TakahashiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Ryoko TanakaDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Kohei SaijoDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Jo OmataDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yusuke YokoyamaDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Ryusuke ShodoDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yushi UekiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Keisuke YamazakiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Hisayuki OtaDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Takafumi TogashiDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Nao TakahashiDepartment of Otorhinolaryngology, Nagaoka Red Cross Hospital, Niigata, Japan.
Ryuichi OkabeDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Hiroshi MatsuyamaDepartment of Otorhinolaryngology, Niigata City General Hospital, Niigata, Japan.
Arata HoriiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Niigata University · JPNiigata Cancer Center Hospital · JPNagaoka Red Cross Hospital · JPNiigata City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The global standard for chemoradiation therapy (CCRT) for head and neck squamous cell carcinoma is cisplatin 100 mg/m Methods: A phase 2 study on CCRT with a 3-weekly cisplatin dose of 80 mg/m Results: The median follow-up period was 61 months. The 5-year progression-free survival/overall survival of all 47 patients was 66.0%/76.6%, while that of patients with stage III, IV disease (UICC) was 65.6%/71.9%. Seventeen patients (36%) experienced dysphagia as a late adverse event. Univariate and multivariate analyses revealed a significant association between acute mucositis/low body mass index (BMI) during CCRT and late dysphagia. Conclusion: The survival outcomes of CCRT with a 3-weekly cisplatin dose of 80 mg/m

Indexed as

3-weekly CDDP 80 mg/m 25-year survival datachemoradiotherapyhead and neck cancerlate adverse eventssquamous cell carcinoma

Identifiers

PMID36589621
PMCPMC9800777
OpenAlexW4313272699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.